Ultima OXA 50

Ultima OXA 50 (Oxandrolone 50mg) | NexorinPharma

Ultima OXA 50 is an oral anabolic steroid containing 50mg of Oxandrolone per tablet. At NexorinPharma, we carry Ultima OXA 50 as part of our oral anabolic steroid inventory for customers in markets where Oxandrolone is legally available.

Oxandrolone is the active compound in Ultima OXA 50. It is one of the most clinically documented anabolic steroids available and carries active FDA approval for specific medical indications. The 50mg concentration of Ultima OXA 50 represents a significantly higher dose per tablet than the standard pharmaceutical grade Oxandrolone tablet formats of 2.5mg and 10mg. This distinction is important context for anyone researching this specific product.

Like all anabolic-androgenic steroids, Ultima OXA 50 carries significant health and legal considerations. This page covers what Oxandrolone is, how it works, and what health and legal considerations apply. It does not constitute medical advice. It does not recommend or encourage steroid use. It does not provide dosage, cycle, or stacking guidance of any kind.

Product Specifications

Website: nexorinpharma.com Product Name: Ultima OXA 50 Manufacturer: Ultima Pharmaceuticals Active Compound: Oxandrolone Also Known As: Anavar, Var, Oxandrin Drug Class: Anabolic-androgenic steroid, 17-alpha alkylated oral steroid, DHT derivative Concentration: 50mg per tablet Presentation: Oral tablet Form: Tablet Half-Life: Approximately 9 to 10 hours Route of Administration: Oral Anabolic Rating: 322 to 630 relative to testosterone baseline of 100 Androgenic Rating: 24 relative to testosterone baseline of 100 Aromatization: None 17-Alpha Alkylated: Yes Liver Toxicity: Mild to moderate Legal Status: Schedule III controlled substance in the United States. Prescription required. Legal status varies by country.

About Ultima Pharmaceuticals

Ultima Pharmaceuticals is an internationally recognized non-prescription anabolic steroid manufacturer. The brand produces a comprehensive range of injectable and oral anabolic steroid products for markets where such compounds are legally available. It carries a consistent presence in international bodybuilding and performance communities.

Like all manufacturers operating outside regulated pharmaceutical channels, Ultima Pharmaceuticals does not carry the manufacturing oversight, regulatory scrutiny, or clinical trial documentation of pharmaceutical grade prescription products. Consequently, quality, purity, and concentration accuracy are less verifiable than with regulated products. Within the non-prescription market, Ultima Pharmaceuticals is consistently referenced for product range breadth and brand consistency.

What Is Oxandrolone

Oxandrolone is a synthetic anabolic-androgenic steroid derived from Dihydrotestosterone. Searle Laboratories developed it in 1962 and introduced it to the US market under the brand name Anavar in 1964. From the beginning, it was developed with a specific goal: produce a compound with strong anabolic activity and minimal androgenic effects.

Structurally, Oxandrolone is a modified form of DHT. Two key structural modifications define it. First, a methyl group at the 17-alpha position allows it to survive first-pass liver metabolism when taken orally. Second, an oxygen atom replaces the carbon-2 atom in the A-ring of the steroid structure. This second modification is directly responsible for Oxandrolone’s unusually high anabolic-to-androgenic ratio and its resistance to aromatization.

Together, these modifications produce an oral anabolic steroid with an anabolic rating of 322 to 630 and an androgenic rating of only 24 relative to a testosterone baseline of 100. Strong anabolic activity combined with very low androgenic potency and no estrogenic conversion defines its pharmacological profile entirely.

How Oxandrolone Works

Oxandrolone is active when taken orally. The 17-alpha alkylation allows it to pass through the liver without complete breakdown, reaching systemic circulation in active form.

Androgen Receptor Binding

Oxandrolone binds to androgen receptors throughout the body. Its androgenic activity is significantly lower than testosterone despite its high anabolic rating. As a result, androgen receptor activation in muscle tissue drives its anabolic effects while producing comparatively minimal androgenic activity in androgen-sensitive tissues like skin and hair follicles.

Nitrogen Retention

Oxandrolone produces positive nitrogen retention in muscle tissue. The body retains more nitrogen than it excretes. Consequently, this supports an anabolic environment that favors muscle repair and preservation. This mechanism is particularly relevant in clinical contexts where muscle wasting prevention is a primary treatment goal.

Protein Synthesis

Oxandrolone accelerates protein synthesis in skeletal muscle tissue. Faster protein synthesis supports muscle repair and growth following training or tissue stress. This mechanism is directly tied to its anabolic receptor activity and contributes to its documented clinical efficacy across multiple indications.

No Aromatization

Oxandrolone does not convert to estrogen through the aromatase enzyme pathway. As a DHT derivative, it is not a substrate for aromatase. Consequently, estrogen-related side effects including water retention and gynecomastia are not part of its direct pharmacological profile. This characteristic distinguishes Oxandrolone from testosterone and many other anabolic steroids where estrogenic conversion is a primary side effect consideration.

IGF-1 Stimulation

Oxandrolone increases Insulin-like Growth Factor 1 production. IGF-1 plays a direct role in muscle repair, recovery, and anabolic activity throughout the body. This mechanism contributes to the muscle preservation and recovery effects documented across Oxandrolone’s clinical research base.

Creatine Phosphate Synthesis

Oxandrolone enhances creatine phosphate synthesis in muscle tissue. Creatine phosphate is a primary energy substrate for high-intensity muscular activity. As a result, enhanced creatine phosphate availability supports strength and power output during physical activity.

Clinical Background

Oxandrolone carries a more extensive clinical history than virtually any other anabolic steroid discussed in performance communities. This background provides important context for its pharmacological profile and documented effects.

FDA Approval and Current Indications

The FDA approved Oxandrolone under the brand name Oxandrin, currently produced by Savient Pharmaceuticals. Unlike most anabolic steroids, Oxandrolone retains active FDA approval today. Its current approved indications include weight regain following involuntary weight loss associated with surgery, chronic infection, trauma, or prolonged corticosteroid use. It is also approved for the treatment of bone pain associated with osteoporosis.

HIV and AIDS-Related Muscle Wasting

Oxandrolone has extensive clinical research documentation in the treatment of HIV and AIDS-related muscle wasting. Multiple controlled clinical trials document its efficacy in preserving and restoring lean body mass in HIV-positive patients experiencing involuntary weight loss. This clinical application represents one of the most well-documented uses of any anabolic steroid in modern medical research.

Burns and Wound Healing

Clinical research documents Oxandrolone’s efficacy in accelerating recovery and preserving lean body mass in severe burn patients. Studies in both pediatric and adult burn patients demonstrate meaningful improvements in recovery outcomes with Oxandrolone use under medical supervision. As a result, burn treatment represents one of its most consistently supported clinical applications.

Turner Syndrome

Researchers have studied and used Oxandrolone clinically in girls with Turner syndrome to promote linear growth. This pediatric application reflects its documented low androgenic activity and relative safety profile compared to other anabolic steroids at appropriate clinical doses.

Alcoholic Hepatitis

Clinical research has examined Oxandrolone in the treatment of alcoholic hepatitis. Its anabolic properties and relatively mild liver impact compared to other oral anabolic steroids make it a relevant research compound in this context. This represents a distinct clinical application outside of muscle wasting and growth indications entirely.

About the 50mg Concentration

The 50mg per tablet concentration of Ultima OXA 50 significantly exceeds the standard pharmaceutical clinical tablet formats for Oxandrolone. Understanding this distinction is important context for anyone researching this specific product.

Comparison With Standard Clinical Formats

The FDA-approved Oxandrin product is available in 2.5mg and 10mg tablet formats. Ultima OXA 50 contains 50mg of Oxandrolone per tablet, which is five times the concentration of the maximum standard pharmaceutical tablet format. This significantly higher concentration per tablet carries considerably greater side effect considerations compared to standard clinical dose formats. Anyone researching Ultima OXA 50 should understand this distinction clearly.

Non-Prescription Market Context

Higher concentration Oxandrolone tablet formats including 25mg, 40mg, and 50mg are produced by various manufacturers in non-prescription markets. Ultima OXA 50 sits at the higher end of these non-prescription concentration formats. As a result, the side effect considerations associated with higher Oxandrolone concentrations are particularly relevant to this specific product compared to lower concentration formats.

Liver Considerations at Higher Concentrations

Oxandrolone’s generally mild hepatotoxicity profile is documented at standard clinical doses of 2.5mg to 20mg. The 50mg concentration of Ultima OXA 50 represents a substantially higher per-tablet concentration than standard clinical formats. Consequently, liver stress considerations are more pronounced at this concentration than the clinical research base at standard doses fully reflects.

Ultima OXA 50 Versus Other Oxandrolone Products and Oral Anabolic Steroids

Versus Osteovar Oxandrolone 10mg USP

Osteovar Oxandrolone 10mg USP contains the same active compound as Ultima OXA 50 at a significantly lower concentration per tablet. The USP designation on Osteovar indicates compliance with United States Pharmacopeia standards for compound identity and purity. Ultima OXA 50 provides a higher concentration per tablet at 50mg, which is five times the Osteovar concentration. This distinction carries meaningful side effect and liver stress considerations.

Versus Oxapex 25

Oxapex 25 contains the same active compound at 25mg per tablet, half the concentration of Ultima OXA 50. Both are non-prescription Oxandrolone preparations. The 50mg concentration of Ultima OXA 50 consequently carries greater side effect considerations per tablet compared to the 25mg Oxapex format.

Versus Methandrostenolone (Dianabol)

Methandrostenolone is a 17-alpha alkylated oral anabolic steroid that aromatizes significantly to estrogen. It carries significant liver toxicity, pronounced estrogenic side effects, and a more aggressive overall side effect profile. Ultima OXA 50, on the other hand, produces no estrogenic conversion and significantly lower androgenic activity. As a result, Oxandrolone represents a considerably milder pharmacological profile than Methandrostenolone across most side effect parameters even at the higher 50mg concentration.

Versus Oxymetholone (Anadrol)

Oxymetholone is one of the most potent oral anabolic steroids available. It carries significant liver toxicity and pronounced estrogenic effects despite not directly aromatizing. Compared to Oxymetholone, Ultima OXA 50 produces dramatically lower liver stress, no estrogenic conversion, and a significantly more favorable side effect profile overall even at its higher 50mg concentration.

Versus Stanozolol (Winstrol)

Stanozolol is a non-aromatizing oral anabolic steroid and fellow DHT derivative. Both compounds do not convert to estrogen. However, Stanozolol carries more significant liver toxicity and more pronounced adverse lipid effects than Oxandrolone. In addition, Stanozolol’s androgenic activity exceeds Oxandrolone’s very low androgenic rating of 24. Ultima OXA 50 consequently represents a milder androgenic and hepatotoxicity profile than Stanozolol even at the higher 50mg concentration.

Versus Turinabol

Turinabol is a non-aromatizing oral anabolic steroid with a moderate anabolic profile. Both Turinabol and Oxandrolone are non-aromatizing oral compounds. However, Oxandrolone carries active FDA approval and a significantly more extensive clinical research base than Turinabol. Furthermore, Oxandrolone’s anabolic rating substantially exceeds Turinabol’s more moderate anabolic activity.

Side Effects and Health Risks

Ultima OXA 50 carries a side effect profile that reflects both Oxandrolone’s generally mild pharmacological characteristics and the additional considerations introduced by its significantly higher 50mg concentration per tablet.

Liver Toxicity

Oxandrolone is a 17-alpha alkylated oral steroid. The alkylation that allows oral bioavailability places stress on liver tissue. Oxandrolone’s liver toxicity is consistently documented as milder than other 17-alpha alkylated oral anabolic steroids at standard clinical doses. However, the 50mg concentration of Ultima OXA 50 represents a substantially higher per-tablet dose than standard clinical formats. As a result, liver monitoring through regular blood work is particularly important for anyone using this specific high-concentration format.

Cardiovascular Effects

Oxandrolone produces adverse lipid profile changes. HDL cholesterol decreases while LDL cholesterol increases. These lipid changes carry long-term cardiovascular health implications. Furthermore, the higher 50mg concentration per tablet compared to standard clinical formats increases the relevance of cardiovascular monitoring. Regular lipid monitoring is therefore important for anyone using this compound.

Androgenic Effects

Despite its very low androgenic rating of 24, Oxandrolone still produces androgenic side effects in susceptible individuals. These include accelerated hair loss in genetically predisposed individuals and acne. In women, virilization risks including voice deepening and clitoral enlargement are serious considerations even at lower doses given Oxandrolone’s anabolic potency. At the 50mg concentration of Ultima OXA 50, these risks are more pronounced than at standard clinical formats.

Hormonal Suppression

Oxandrolone suppresses the hypothalamic-pituitary-gonadal axis and the body’s natural testosterone production. The degree of suppression is generally considered less pronounced than with more potent anabolic steroids. However, post-use hormonal disruption remains a relevant consideration. In some cases, it results in hypogonadism requiring medical treatment.

Psychological Effects

Anabolic steroid use carries documented associations with mood changes and irritability. These considerations apply to Oxandrolone use at any concentration. They are generally less pronounced than with higher androgenic compounds but remain relevant health considerations at the 50mg concentration of Ultima OXA 50.

Legal and Regulatory Status

Oxandrolone retains active FDA approval under the brand name Oxandrin for specific clinical indications. Outside of those indications, however, it carries Schedule III controlled substance status in the United States. Possession without a valid prescription is a federal offense.

In the United Kingdom, Oxandrolone falls under Class C of the Misuse of Drugs Act. Supply is illegal.

The World Anti-Doping Agency bans Oxandrolone alongside all major athletic governing bodies. It consequently appears on prohibited substance lists across Olympic sports, professional athletics, and competitive bodybuilding organizations that conduct testing.

You are responsible for confirming the legal status of Oxandrolone in your specific jurisdiction before purchasing from NexorinPharma.

Frequently Asked Questions

Is Ultima OXA 50 Available at NexorinPharma

Yes. NexorinPharma carries Ultima OXA 50 for customers in markets where Oxandrolone is legally available. Visit nexorinpharma.com to check current availability and pricing.

What Is the Half-Life of Oxandrolone

Oxandrolone produces a half-life of approximately 9 to 10 hours. As a result, active plasma concentrations are sustained longer than shorter half-life oral anabolic steroids while still requiring regular oral administration to maintain stable levels.

Does Oxandrolone Aromatize

No. Oxandrolone does not convert to estrogen through the aromatase enzyme pathway. As a DHT derivative, it is not a substrate for aromatase. Consequently, estrogen-related side effects are not part of its direct pharmacological profile.

How Does the 50mg Concentration Compare to Standard Clinical Oxandrolone Formats

The FDA-approved Oxandrin product is available in 2.5mg and 10mg tablet formats. The 50mg concentration of Ultima OXA 50 consequently exceeds the maximum standard pharmaceutical tablet format by five times. This significantly higher concentration per tablet carries considerably greater side effect considerations compared to standard clinical formats.

How Does Ultima OXA 50 Compare to Osteovar 10mg and Oxapex 25

All three products contain Oxandrolone as the active compound. Osteovar provides 10mg per tablet with a USP designation. Oxapex 25 provides 25mg per tablet. Ultima OXA 50 provides the highest concentration at 50mg per tablet. As a result, Ultima OXA 50 carries the greatest per-tablet side effect considerations of the three formats.

What Are the Most Serious Health Risks

Liver toxicity considerations at the higher 50mg concentration and cardiovascular effects from lipid dysregulation are among the most clinically significant concerns. In addition, hormonal suppression, androgenic effects, and psychological impacts complete the primary risk profile. Medical supervision and regular blood work monitoring are therefore essential for anyone using this compound.

Is Ultima OXA 50 Legal to Purchase

Oxandrolone carries Schedule III controlled substance status in the United States and requires a valid prescription despite retaining active FDA approval for specific indications. Legal status varies by jurisdiction. You are responsible for confirming the legal status in your jurisdiction before purchasing from NexorinPharma.

What to Consider Before Purchasing Ultima OXA 50

Oxandrolone has one of the most extensive clinical research bases of any anabolic steroid discussed in performance communities. Its active FDA approval, documented clinical applications across multiple indications, and decades of controlled clinical trial data provide a substantially stronger research foundation than most anabolic steroids carry.

The 50mg concentration of Ultima OXA 50 significantly exceeds standard clinical tablet formats. As a result, the side effect considerations associated with higher Oxandrolone concentrations are considerably more relevant to this specific product than to standard clinical dose formats. The clinical research base for Oxandrolone at standard doses provides a relevant pharmacological framework. However, it does not fully represent the risk profile at the 50mg concentration outside of clinical supervision.

Oxandrolone carries documented cardiovascular, liver, hormonal, androgenic, and psychological health risks. These risks require medical supervision to manage responsibly. Regular blood work monitoring including liver enzymes, lipid panels, and hormone levels is therefore essential for anyone using this compound.

For customers in markets where Oxandrolone is legally available, visit nexorinpharma.com to check current Ultima OXA 50 availability, pricing, and stock levels.